Human fetal pancreas--a potential source for transplantation

Area of Science:

• Regenerative Medicine
• Endocrinology
• Immunology

Background:

• Human fetal pancreas (HFP) is a promising source for treating diabetes.
• HFP transplantation offers advantages over whole organ transplants.
• Key challenges include demonstrating efficacy, glucose responsiveness, and reduced immunogenicity.

Purpose of the Study:

• To evaluate HFP's ability to reverse experimentally induced diabetes.
• To assess the in vivo function and glucose responsiveness of transplanted HFP.
• To investigate the reduction of immunogenicity in HFP grafts.

Main Methods:

• Transplantation of HFP (13-17 weeks gestational age) into streptozotocin-induced diabetic nude mice.
• Monitoring of glycemic control and performance of oral glucose tolerance tests.
• In vitro insulin secretion assays and immunohistological analysis of human passenger leukocytes.

Main Results:

• 88% of transplanted mice achieved normoglycemia within 6-8 weeks.
• Grafted HFP demonstrated glucose-responsive insulin secretion, unlike fresh fetal tissue.
• Human passenger leukocyte levels significantly decreased by 32 weeks post-transplant.

Conclusions:

• Transplanted HFP differentiates and matures in a diabetic mouse model.
• HFP exhibits functional suitability for transplantation in diabetic patients.
• Reduced immunogenicity enhances the potential for clinical application.